Antibody-drug conjugate · Cytotoxic, directed at CD166 (ALCAM) (ALCAM) · developed by CytomX Therapeutics
Praluzatamab ravtansine (CX-2009) is a probody drug conjugate in which an anti-CD166 antibody, masked by a cleavable peptide, carries the cytotoxic maytansinoid DM4. The masking peptide is cleaved by proteases in the tumor microenvironment, allowing the antibody to bind CD166-expressing tumor cells; released DM4 binds tubulin and disrupts microtubule dynamics. It is studied in breast cancer, including triple-negative and hormone receptor-positive/HER2-negative disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04596150 | Phase 2 | Neoplasms | Completed | CTMX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerBreast NeoplasmsBreast Neoplasms, Hormone Receptor Positive/HER2 NegativeBreast Neoplasms, Triple-NegativeNeoplasms
Updated Nov 8, 2026. Something wrong or missing? Report it on the CTMX page.
See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CTMX catalysts and pipeline →